A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Luc Friboulet, Nanxin Li, Ryohei Katayama et al. · Cancer Discovery · 2014 · 842 citations · Full text

Medicine, Oncology, Pharmacology +15

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

Scott C. Bresler, Daniel A. Weiser, Peter J. Huwe et al. · Cancer Cell · 2014 · 387 citations · Full text

Medicine, Molecular Genetics, Oncology +12

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

Ryohei Katayama, Luc Friboulet, Sumie Koike et al. · Clinical Cancer Research · 2014 · 286 citations · Full text

Medicine, Oncology, Pharmacology +15

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Johannes M. Heuckmann, Hyatt Balke‐Want, Florian Malchers et al. · Clinical Cancer Research · 2012 · 259 citations

Medicine, Oncology, Pharmacology +14

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

S.-H.I. Ou, Pasi A. Jänne, Cynthia Huang Bartlett et al. · Annals of Oncology · 2014 · 220 citations · Full text

Medicine, Oncology, Pharmacology +14